Teva Pharmaceutical Industries Ltd. (TEVA) Reached the 52-Week High of $47.77
Teva Pharmaceutical Industries Ltd. Develops, manufactures, and markets generic pharmaceuticals. The company markets a variety of dosage forms including both extended and immediate release tablets and capsules creams, ointments, solutions, and suspensions. Teva Pharmaceutical Industries Ltd. has a market cap of $42.45 billion; its shares were traded at around $47.77 with a P/E ratio of 16.9 and P/S ratio of 3.8. The dividend yield of Teva Pharmaceutical Industries Ltd. stocks is 0.9%. Teva Pharmaceutical Industries Ltd. had an annual average earning growth of 42.6% over the past 10 years. GuruFocus rated Teva Pharmaceutical Industries Ltd. the business predictability rank of 2.5-star.
Teva Pharmaceutical Industries Ltd. recently reported net sales of $3.15 billion, up 22% compared to the first quarter of 2008. Non-GAAP net income was $634 million, up 4% compared with the first quarter of 2008. GAAP net income totaled $451 million.
TEVA is in the portfolios of Ken Heebner of CAPITAL GROWTH MANAGEMENT LP, Sarah Ketterer of CAUSEWAY CAPITAL MANAGEMENT LLC, and Kenneth Fisher of Fisher Asset Management, LLC.
No comments:
Post a Comment